Llwytho...
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms
BACKGROUND: Ibrutinib is an orally administered inhibitor of Bruton’s tyrosine kinase (Btk). Preclinical data suggest that mast cells are recruited within neuroendocrine neoplasms (NENs) where they stimulate angiogenesis and tumor growth. Ibrutinib inhibits mast cell degranulation and has been assoc...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Neuroendocrinology |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7771542/ https://ncbi.nlm.nih.gov/pubmed/31357193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000502383 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|